

Gemini Announces Additions to Executive Leadership Team

** O’Neil, former Group Head at Millipore Sigma, joins as Chief Commercial Officer*

** Lucey, former Senior BD Manager at Sartorius, joins as VP of Business Development*

New York, NY and West Sacramento, CA – June 3, 2019 – Gemini Bio-Products, LLC (“Gemini” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced the appointment of two new members of the senior executive team.

Gemini named Donald O’Neil as Chief Commercial Officer (“CCO”). Don has over 20 years of relevant life sciences experience. His previous roles include responsibilities for Invitrogen’s global reagents business, now owned by Thermo Fisher (NYSE: TMO), and MilliporeSigma’s (ETR: MRK) Cell Biology and Detection Solutions business segments. He was most recently SVP of Sales and Strategic Partnerships at ORFLO Technologies, a life science instruments company. Don will lead Gemini’s commercial efforts, across a 14-person sales and marketing team.

Gemini also named Brendan Lucey as Vice President of Business Development. Brendan has over 17 years of industry experience, including roles as an executive at PE-backed ILC Dover, Sartorius Stedim (EPA: DIM), a leading biopharma tools company, and Lonza (SWX: LONN), a leading contract development and manufacturing organization. Brendan’s background aligns him well with Gemini’s life science ecosystem. He will be a key driver of the Company’s deeper penetration into the biotech industry channel across sales, OEM and distribution partnerships. Brendan also serves on the Board of Bioprocess Systems Alliance (BPSA), an industry group focused on single use biologics manufacturing.

Dale Gordon, CEO of Gemini, stated “I am thrilled to welcome Don and Brendan to the Gemini team. I have known Don for over 10 years, and strongly believe that his industry experience in the cell culture space will be instrumental in leading Gemini’s sales and marketing organization. Furthermore, Brendan’s scientific expertise and leadership in continuous manufacturing will bolster Gemini’s strategic partnerships. With our well-rounded management team, I look forward to continuing Gemini’s growth in providing high quality products and services to our customers across cell and gene therapy, biotechnology, and academic research.”

About Gemini Bio-Products

Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top research and academic communities, biotechnology firms, and pharmaceutical companies. Today, Gemini operates from its headquarters in West Sacramento, California. A national sales force and an international distribution network serves cell culture laboratories worldwide.

About BelHealth Investment Partners

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current \$350 million fund.

For further information, please visit:

BelHealth Investment Partners: www.belhealth.com

Contact:

BelHealth Investment Partners: Inder Tallur (347) 308-7018

Gemini Bio-Products: Dale Gordon (916) 273-5228